PT - JOURNAL ARTICLE AU - Eli Mansour AU - Andre C. Palma AU - Raisa G. Ulaf AU - Luciana C. Ribeiro AU - Ana Flavia Bernardes AU - Thyago A. Nunes AU - Marcus V. Agrela AU - Bruna Bombassaro AU - Milena Monfort-Pires AU - Rafael L. Camargo AU - Eliana P. Araujo AU - Natalia S. Brunetti AU - Alessandro S. Farias AU - Antônio Luís E. Falcão AU - Thiago Martins Santos AU - Plinio Trabasso AU - Rachel P. Dertkigil AU - Sergio S. Dertkigil AU - Maria Luiza Moretti AU - Licio A. Velloso TI - Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 – A proof-of-concept study AID - 10.1101/2020.08.11.20167353 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.11.20167353 4099 - http://medrxiv.org/content/early/2020/08/14/2020.08.11.20167353.short 4100 - http://medrxiv.org/content/early/2020/08/14/2020.08.11.20167353.full AB - Coronavirus disease-19 (COVID-19) can develop into a severe respiratory syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major pathological finding in autopsies explaining O2 diffusion failure and hypoxemia. Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity. SARS-CoV-2 enters cells employing angiotensin converting enzyme 2 (ACE2) as a receptor, which is highly expressed in lung alveolar cells. ACE2 is one of the components of the cellular machinery that inactivates the potent inflammatory agent bradykinin, and SARS-CoV-2 infection could interfere with the catalytic activity of ACE2, leading to accumulation of bradykinin. In this open-label, randomized clinical trial, we tested two pharmacological inhibitors of the kinin-kallikrein system that are currently approved for the treatment of hereditary angioedema, icatibant and inhibitor of C1 esterase/kallikrein, in a group of 30 patients with severe COVID-19. Neither icatibant nor inhibitor of C1 esterase/kallikrein resulted in significant changes in disease mortality and time to clinical improvement. However, both compounds promoted significant improvement of lung computed tomography scores and increased blood eosinophils, which has been reported as an indicator of disease recovery. In this small cohort, we found evidence for a beneficial role of pharmacological inhibition of the kinin-kallikrein system in two markers that indicate improved disease recovery.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial(UTN): U1111-1250-1843Funding StatementGrant providers. Sao Paulo Research Foundation grants #2013/07607-8 and #2020/04522-5; University of Campinas grant #2298/20.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Review Committee of the Clinics Hospital of the University of Campinas (protocol CAEE: 30227920.9.0000.5404).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request